Presentations

Our Presentations

19 September 2023 – GSS Investor Presentation

This presentation provides an update on the Company's US Commercial Launch

Download the presentation slides here

4 September 2023 – Genetic Signatures (ASX:GSS)

FDA 510(k) Filing in Preparation for US Commercial Launch.

Click to download

August 2023 – Genetic Signatures’ CEO, John Melki interview for TechInvest Magazine

Dr. Melki speaking with David Tasker Managing Director of Chapter One Advisors for TechInvest Magazine

1st & 3rd August 2023 – Genetic Signatures’ CEO, John Melki at TechKnow Invest Roadshow

Dr. Melki speaking at TechKnow Invest Roadshow which was held in Queensland and Melbourne Australia August 2023

ShareCafe Webinar - GSS Dec 2022

28 October 2022 – Genetic Signatures’ CEO, John Melki, talks with Nadine Blayney from AusBiz

Genetic Signatures' CEO Dr John Melki was recently interviewed by Nadine Blayney from AusBiz about the Company’s unique 3base® technology, its advantages for detecting infectious diseases, the development pipeline, revenue sources, and plans for further investment and expansion in key international markets.

18 October 2022 – GSS Investor Presentation

This presentation provides an update on the Company’s finance performance for FY22, progress of the Enteric Protozoan Kit in North America, and new areas of growth.

Click to download

7 September 2022 – GSS Investor Presentation

This presentation provides an update on the Company’s FY22 performance, new assay and instrument development, and key activities in North America and Europe.

Click to download

27 April 2022 – GSS Investor Presentation

This presentation provides an update on the Company’s Q3 2022 performance, highlights key achievements and activities, and features the product portfolio and developments in the product pipeline.

Click to download

20 April 2022 - AusBiz Presentation with David Koch

Genetic Signatures' CEO Dr John Melki talks with AusBiz host David Koch, discussing the advantages of 3base^TM technology for infectious disease testing, as well as the latest news and developments of the company.

27 January 2022 - Biotech Predictions Webinar Presentation

This presentation provides an update on the Company's latest activities. Watch the presentation below or download the presentation slides here

25 October 2021 - GSS Investor Presentation

This presentation provides an update on the Company's latest activities. Watch the presentation below or download the presentation slides here

13 August 2021 - Investor webinar presentation

Dr John Melki, Genetic Signatures CEO provides an overview of the Company’s specialist molecular diagnostics technology, 3base, which has the ability to screen for a wide array of infectious pathogens with a high degree of specificity in rapid time.

View presentation slides here

13 August 2021 - Investor webinar presentation

Dr John Melki, Genetic Signatures CEO will provide an overview of the Company’s specialist molecular diagnostics technology, 3baseTM which has the ability to screen for a wide array of infectious pathogens, with a high degree of specificity in rapid time.

Click here to view more details.

12 February 2021 - Genetic Signatures ShareCafe Webinar

John Melki, Director & Chief Executive Officer

26 November 2020- The following videos were delivered to participants at the November 2020 Bell Potter Healthcare conference.

John Buckels, Directors Sales & Support Europe

Derek Joesting, Director of Sales North America

Customer representative from Royal Marsden Hospital in London